Skip Navigation

Gregory A. Abel, MD, MPH


Medical Oncology

Make an Appointment

Physician

  • Senior Physician
  • Director, Older Adult Hematologic Malignancy Program
  • Associate Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Leukemia, Myelodysplastic syndromes, Myeloproliferative disorders

Diseases Treated

Contact Information

  • Appointments617-632-6028 (new)
    617-632-1906 (follow-up)
  • Office Phone Number617-632-1906
  • Fax617-632-2933

Bio

Dr. Abel received his MD and MPH from Columbia University in 2000. He completed his postgraduate training in internal medicine at Massachusetts General Hospital and his hematology/oncology fellowship at Dana-Farber Cancer Institute. In 2007, he joined Dana-Farber and is a member of the Hematologic Malignancies staff, as well as the Center for Outcomes and Policy Research.

Board Certification:

  • Internal Medicine, 2003
  • Oncology, 2007

Fellowship:

  • Dana-Farber/Partners CancerCare, Hematology/Oncology

Residency:

  • Massachusetts General Hospital, Internal Medicine

Medical School:

  • Columbia University

Research

Health Services Research, Outcomes Research, Hematologic Malignancies

My research aims to apply health services methods to understand the experiences of patients with cancer and to answer questions about the effectiveness of cancer care. I am also interested in evaluating how intensive cancer therapy affects outcomes other than survival, such as quality of life and financial well-being. I primarily focus on the hematologic malignancies, studying the impact of these diseases and their treatment from diagnosis to the end of life. Specific interests have included the impact of direct-to-consumer advertising in cancer care, utility of surveillance imaging for patients with diffuse large B-cell lymphoma, effects of delays in diagnosis for blood cancers, and therapeutic changes and treatment disparities for patients with multiple myeloma. I have also been fortunate to receive a grant from the Leukemia and Lymphoma Society for a longitudinal study to compare the effectiveness of treatments for older patients with myelodysplastic syndromes (MDS). Another project aims to characterize the financial burden experienced by patients who undergo stem cell transplantation, and whether an increase in that burden is associated with compromised outcomes. Finally, I am interested in expanding and improving the tools available for outcomes research in hematologic oncology. For example, I am developing a new disease-specific measure of quality of life for patients with MDS (the “QUALMS-1”), and have created an MDS prognostic scoring system for use with the large SEER-Medicare dataset.

Odejide OO, Li L, Cronin AM, Murillo A, Richardson PG, Anderson KC, Abel GA. Meaningful changes in end-of-life care among patients with myeloma. Haematologica. 2018 May 10.
View in: PubMed

Frosch ZAK, Cronin AM, Gagne JJ, Teschke MP, Gray SW, Abel GA. Cancer drug shortages: Awareness and perspectives from a representative sample of the US population. Cancer. 2018 May 15; 124(10):2205-2211.
View in: PubMed

Hshieh TT, Jung WF, Grande LJ, Chen J, Stone RM, Soiffer RJ, Driver JA, Abel GA. Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncol. 2018 Mar 01.
View in: PubMed

Khera N, Albelda R, Hahn T, Coronado DS, Odejide OO, Soiffer RJ, Abel GA. Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival. Cancer Epidemiol Biomarkers Prev. 2018 Mar; 27(3):345-347.
View in: PubMed

Frosch ZAK, Gagne JJ, Gray SW, Abel GA. What Does a Cancer Diagnosis Mean? Public Expectations in a Shifting Therapeutic Environment. J Oncol Pract. 2018 Mar; 14(3):139-140.
View in: PubMed

Luskin MR, Abel GA. Management of older adults with myelodysplastic syndromes (MDS). J Geriatr Oncol. 2017 Dec 28.
View in: PubMed

Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci AA, Zhang H, Sprangers M, Vignetti M, Mandelli F. Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. Cancer. 2018 Mar 15; 124(6):1251-1259.
View in: PubMed

Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood. 2018 Feb 01; 131(5):515-524.
View in: PubMed

Brunner AM, Blonquist TM, Hobbs GS, Amrein PC, Neuberg DS, Steensma DP, Abel GA, Fathi AT. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017 Oct 24; 1(23):2032-2040.
View in: PubMed

Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ. Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PLoS One. 2017; 12(9):e0184747.
View in: PubMed

Abel GA. Aptitude; Mother's Day; Winter Beach. J Clin Oncol. 2017 Aug 20; 35(24):2848.
View in: PubMed

Odejide OO, Cronin AM, Earle CC, Tulsky JA, Abel GA. Why are patients with blood cancers more likely to die without hospice? Cancer. 2017 Sep 01; 123(17):3377-3384.
View in: PubMed

Luskin MR, Cronin AM, Owens RL, DeAngelo DJ, Stone RM, Wadleigh M, Steensma DP, Abel GA. Self-reported sleep disturbance and survival in myelodysplastic syndromes. Br J Haematol. 2017 05; 177(4):562-566.
View in: PubMed

Connell NT, Abel GA, Connors JM. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thromb Res. 2017 Feb; 150:53-58.
View in: PubMed

Frosch ZA, Abel GA. Assessing Quality of Care for the Myelodysplastic Syndromes. Curr Hematol Malig Rep. 2016 12; 11(6):402-407.
View in: PubMed

Schnipper LE, Abel GA. Direct-to-Consumer Drug Advertising in Oncology Is Not Beneficial to Patients or Public Health. JAMA Oncol. 2016 Nov 01; 2(11):1397-1398.
View in: PubMed

Nipp RD, Abel GA. Small Step for Geriatric Oncology That Could Have Been a Giant Leap. J Clin Oncol. 2016 Nov 20; 34(33):4048-4049.
View in: PubMed

Zhou Z, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson MM, Zelenetz AD, Niland J, Friedberg JW, Winter JN. High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. J Natl Compr Canc Netw. 2016 10; 14(10):1274-1281.
View in: PubMed

Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016 Dec; 175(5):829-840.
View in: PubMed

Zeidan AM, Wang R, Gross CP, Gore SD, Huntington SF, Prebet T, Abel GA, Davidoff AJ, Ma X. Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. Leuk Lymphoma. 2017 04; 58(4):982-985.
View in: PubMed

Liu MA, Hshieh T, Condron N, Wadleigh M, Abel GA, Driver JA. Relationship between physician and patient assessment of performance status and survival in a large cohort of patients with haematologic malignancies. Br J Cancer. 2016 09 27; 115(7):858-61.
View in: PubMed

Odejide OO, Cronin AM, Condron NB, Fletcher SA, Earle CC, Tulsky JA, Abel GA. Barriers to Quality End-of-Life Care for Patients With Blood Cancers. J Clin Oncol. 2016 Sep 10; 34(26):3126-32.
View in: PubMed

El-Jawahri A, Keenan T, Abel GA, Steensma DP, LeBlanc TW, Chen YB, Hobbs G, Traeger L, Fathi AT, DeAngelo DJ, Wadleigh M, Ballen KK, Amrein PC, Stone RM, Temel JS. Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016 Jun; 3(6):e276-83.
View in: PubMed

Abel GA, Albelda R, Khera N, Hahn T, Salas Coronado DY, Odejide OO, Bona K, Tucker-Seeley R, Soiffer R. Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 08; 22(8):1504-1510.
View in: PubMed

Stuver SO, McNiff K, Fraile B, Odejide O, Abel GA, Dodek A, Jacobson JO. Novel Data Sharing Between a Comprehensive Cancer Center and a Private Payer to Better Understand Care at the End of Life. J Pain Symptom Manage. 2016 08; 52(2):161-9.
View in: PubMed

Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, Lee SJ, List AF, Klaassen RJ. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica. 2016 06; 101(6):781-8.
View in: PubMed

Abel GA, Cronin AM, Odejide OO, Uno H, Stone RM, Steensma DP. Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes. Br J Haematol. 2016 06; 173(5):713-21.
View in: PubMed

Fletcher SA, Cronin AM, Zeidan AM, Odejide OO, Gore SD, Davidoff AJ, Steensma DP, Abel GA. Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer. 2016 Apr 15; 122(8):1209-15.
View in: PubMed

Odejide OO, Cronin AM, Condron N, Earle CC, Wolfe J, Abel GA. Timeliness of End-of-Life Discussions for Blood Cancers: A National Survey of Hematologic Oncologists. JAMA Intern Med. 2016 Feb; 176(2):263-5.
View in: PubMed

Abel GA, Buckstein R. Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes. Am Soc Clin Oncol Educ Book. 2016; 35:e337-44.
View in: PubMed

Cronin A, Watts CD, Steensma DP, Stone RM, DeAngelo DJ, Owens RL, Wadleigh M, Abel GA. Impact of sleep disturbance in myelodysplastic syndromes (MDS). J Clin Oncol. 2015 Oct 10; 33(29_suppl):99.
View in: PubMed

Keenan T, Abel GA, Steensma DP, LeBlanc TW, Traeger L, Fathi AT, DeAngelo DJ, Wadleigh M, Hobbs G, Amrein PC, Stone RM, Ballen KK, Chen YA, Temel JS. Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML). J Clin Oncol. 2015 Oct 10; 33(29_suppl):206.
View in: PubMed

Odejide OO, Cronin AM, Earle CC, LaCasce AS, Abel GA. Hospice Use Among Patients With Lymphoma: Impact of Disease Aggressiveness and Curability. J Natl Cancer Inst. 2016 Jan; 108(1).
View in: PubMed

Abel GA, Cronin AM, Earles K, Gray SW. Accessibility and Quality of Online Cancer-Related Clinical Trial Information for Naïve Searchers. Cancer Epidemiol Biomarkers Prev. 2015 Oct; 24(10):1629-31.
View in: PubMed

Fega KR, Abel GA, Motyckova G, Sherman AE, DeAngelo DJ, Steensma DP, Galinsky I, Wadleigh M, Stone RM, Driver JA. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol. 2015 Jul; 6(4):288-98.
View in: PubMed

El-Jawahri AR, Abel GA, Steensma DP, LeBlanc TW, Fathi AT, Graubert TA, DeAngelo DJ, Wadleigh M, Ballen KK, Foster JE, Attar EC, Amrein PC, Brunner AM, Stone RM, Temel JS. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8.
View in: PubMed

Abel GA. Does surveillance imaging after treatment for diffuse large B-cell lymphoma really work? J Clin Oncol. 2015 May 01; 33(13):1427-9.
View in: PubMed

Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015 Apr 01; 121(7):1032-9.
View in: PubMed

Bona K, London WB, Guo D, Abel G, Lehmann L, Wolfe J. Prevalence and impact of financial hardship among New England pediatric stem cell transplantation families. Biol Blood Marrow Transplant. 2015 Feb; 21(2):312-8.
View in: PubMed

Klaassen R, Efficace F, Buckstein R, Tinsley S, Watts CD, Jurcic JG, Abel GA. Measuring quality of life in chronic hematologic malignancy: The QUALMS-1. J Clin Oncol. 2014 Oct 20; 32(30_suppl):263.
View in: PubMed

Fraile B, Donohue CC, Odejide OO, Abel GA, Dodek A, Fallon JA, Jacobson JO. Novel data sharing between a comprehensive cancer center and a private payer to better understand care at the end of life. J Clin Oncol. 2014 Oct 20; 32(30_suppl):1.
View in: PubMed

Salas Coronado D, Watts CD, Wright AA, Abel GA. Quality of end-of-life care: Are blood cancers different? J Clin Oncol. 2014 Oct 20; 32(30_suppl):195.
View in: PubMed

Odejide OO, Salas Coronado DY, Watts CD, Wright AA, Abel GA. End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract. 2014 Nov; 10(6):e396-403.
View in: PubMed

Uno H, Cronin AM, Wadleigh M, Schrag D, Abel GA. Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS). Leuk Res. 2014 Dec; 38(12):1420-4.
View in: PubMed

Odejide OO, Cronin AM, Davidoff AJ, LaCasce AS, Abel GA. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma. 2015 Mar; 56(3):716-24.
View in: PubMed

Tucker-Seeley RD, Abel GA, Uno H, Prigerson H. Financial hardship and the intensity of medical care received near death. Psychooncology. 2015 May; 24(5):572-8.
View in: PubMed

Abel GA. Public advertising by cancer centers: are more data needed? Ann Intern Med. 2014 Jun 17; 160(12):870-1.
View in: PubMed

Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, LaCasce AS. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer. 2014 Jul 01; 120(13):1993-9.
View in: PubMed

Odejide OO, Jacobson JO, Abel GA. Reply to quality control of bone marrow aspirates: additional steps toward a safer and more efficient procedure. Cancer. 2014 May 01; 120(9):1442.
View in: PubMed

Abel GA, Klaassen R, Lee SJ, Young NL, Cannella L, Steensma DP, Efficace F. Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood. 2014 Jan 16; 123(3):451-2.
View in: PubMed

Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014 Feb 01; 32(4):306-11.
View in: PubMed

Waldman LT, Svoboda L, Young BF, Abel GA, Berlin S, Elfiky AA, Freedman RA, Drews M, Holland L, Lathan CS. A novel community-based delivery model to combat cancer disparities. Healthc (Amst). 2013 Dec; 1(3-4):123-9.
View in: PubMed

Waldman LT, Bean W, Levine AL, Cohen-Bearak A, Phelps FA, Svoboda L, Freedman R, Elfiky A, Berlin S, Abel GA, Deutsch C, Lathan CS. Using FastTrack to Implement an Academic Medical Center and Community Health Center Collaborative for Cancer Care Delivery. Healthc (Amst). 2013 Dec; 1(3-4):130-135.
View in: PubMed

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 06; 123(6):837-42.
View in: PubMed

Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol. 2013 Nov; 163(4):487-95.
View in: PubMed

Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res. 2014 Apr; 23(3):825-36.
View in: PubMed

Odejide OO, Cronin AM, DeAngelo DJ, Bernazzoli ZA, Jacobson JO, Rodig SJ, LaCasce AS, Mazeika TJ, Earles KD, Abel GA. Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist. Cancer. 2013 Oct 01; 119(19):3472-8.
View in: PubMed

Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg JW. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer. 2013 Oct 15; 119(20):3662-71.
View in: PubMed

Sherman AE, Motyckova G, Fega KR, Deangelo DJ, Abel GA, Steensma D, Wadleigh M, Stone RM, Driver JA. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res. 2013 Sep; 37(9):998-1003.
View in: PubMed

Warren JL, Harlan LC, Stevens J, Little RF, Abel GA. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol. 2013 Jun 01; 31(16):1984-9.
View in: PubMed

Abel GA, Koreth J. Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. Curr Opin Hematol. 2013 Mar; 20(2):150-6.
View in: PubMed

Abou-Nassar KE, Vanderplas A, Friedberg JW, Abel GA, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby A, Gordon LI, Zelenetz AD, Kaminski M, Lacasce AS. Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Leuk Lymphoma. 2013 Oct; 54(10):2155-62.
View in: PubMed

Abel GA, Chen K, Taback N, Hassett MJ, Schrag D, Weeks JC. Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions. Cancer. 2013 Mar 01; 119(5):1065-72.
View in: PubMed

Okam MM, Mandell E, Hevelone N, Wentz R, Ross A, Abel GA. Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol. 2012 Nov; 87(11):E123-4.
View in: PubMed

Abel GA, Friese CR, Neville BA, Wilson KM, Hastings BT, Earle CC, Keating NL, Richardson LC. Referrals for suspected hematologic malignancy: a survey of primary care physicians. Am J Hematol. 2012 Jun; 87(6):634-6.
View in: PubMed

Gray SW, Abel GA. Update on Direct-to-Consumer Marketing in Oncology. J Oncol Pract. 2012 Mar; 8(2):124-7.
View in: PubMed

Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, LaCasce AS. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma. 2012 Jun; 53(6):1113-6.
View in: PubMed

LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012 Mar 01; 119(9):2093-9.
View in: PubMed

Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012 Jun 01; 118(11):2944-51.
View in: PubMed

Bertrand KA, Chang ET, Abel GA, Zhang SM, Spiegelman D, Qureshi AA, Laden F. Sunlight exposure, vitamin D, and risk of non-Hodgkin lymphoma in the Nurses' Health Study. Cancer Causes Control. 2011 Dec; 22(12):1731-41.
View in: PubMed

Abel GA. The real world: CLL. Blood. 2011 Mar 31; 117(13):3481-2.
View in: PubMed

Yung RL, Chen K, Abel GA, Gesten FC, Roohan PJ, Boscoe FP, Sinclair AH, Schymura MJ, Schrag D. Cancer disparities in the context of Medicaid insurance: a comparison of survival for acute myeloid leukemia and Hodgkin's lymphoma by Medicaid enrollment. Oncologist. 2011; 16(8):1082-91.
View in: PubMed

Friese CR, Earle CC, Magazu LS, Brown JR, Neville BA, Hevelone ND, Richardson LC, Abel GA. Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia. Cancer. 2011 Apr 01; 117(7):1470-7.
View in: PubMed

Abel GA, Bertrand KA, Earle CC, Laden F. Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program. Hematol Oncol. 2010 Sep; 28(3):133-6.
View in: PubMed

Abel GA, Van Bennekom CM, Stone RM, Anderson TE, Kaufman DW. Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients. Leuk Res. 2010 Jul; 34(7):939-41.
View in: PubMed

Abel GA, Burstein HJ, Hevelone ND, Weeks JC. Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment. J Clin Oncol. 2009 Sep 01; 27(25):4182-7.
View in: PubMed

Friese CR, Abel GA, Magazu LS, Neville BA, Richardson LC, Earle CC. Diagnostic delay and complications for older adults with multiple myeloma. Leuk Lymphoma. 2009 Mar; 50(3):392-400.
View in: PubMed

LaCasce AS, Kho ME, Friedberg JW, Niland JC, Abel GA, Rodriguez MA, Czuczman MS, Millenson MM, Zelenetz AD, Weeks JC. Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol. 2008 Nov 01; 26(31):5107-12.
View in: PubMed

Abel GA, Neufeld EJ, Sorel M, Weeks JC. Direct-to-consumer advertising for bleeding disorders: a content analysis and expert evaluation of advertising claims. J Thromb Haemost. 2008 Oct; 6(10):1680-4.
View in: PubMed

Abel GA, Friese CR, Magazu LS, Richardson LC, Fernandez ME, De Zengotita JJ, Earle CC. Delays in referral and diagnosis for chronic hematologic malignancies: a literature review. Leuk Lymphoma. 2008 Jul; 49(7):1352-9.
View in: PubMed

Abel GA, DeAngelo DJ, Connors JM, Sholl LM, McCaffrey RP, Longtine JA. Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations. Am J Hematol. 2008 Jun; 83(6):519-20.
View in: PubMed

Abel GA, Glinert LH. Chemotherapy as language: sound symbolism in cancer medication names. Soc Sci Med. 2008 Apr; 66(8):1863-9.
View in: PubMed

Abel GA, Lee SJ, Weeks JC. Direct-to-consumer advertising in oncology: a content analysis of print media. J Clin Oncol. 2007 Apr 01; 25(10):1267-71.
View in: PubMed

Abel GA, Penson RT, Joffe S, Schapira L, Chabner BA, Lynch TJ. Direct-to-consumer advertising in oncology. Oncologist. 2006 Feb; 11(2):217-26.
View in: PubMed

Abel GA, Hays JT, Decker PA, Croghan GA, Kuter DJ, Rigotti NA. Effects of biochemically confirmed smoking cessation on white blood cell count. Mayo Clin Proc. 2005 Aug; 80(8):1022-8.
View in: PubMed

Abel GA. Reporting enrollment in clinical trials. Ann Intern Med. 2002 Dec 17; 137(12):1007-8; author reply 1007-8.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1106
Boston MA, 02215
Get Directions

Brigham and Women's Hospital
221 Longwood Ave.
Boston MA, 02115
Get Directions

Top